The USPTO’s Christine Foster ist still not happy with the triage/trauma NGAL-patent, as the recent development shows.

Triage/Trauma Patent – prosecutions remarks july 2012

While she (CF) seems to acknowledge that the double patenting may be erroneous – she maintains that position until other problems have been solved. On the other hand she maintains that the “new” claim 1 is not applicable as it is differs from what is allowed in finally rejected claims – and secondly that the new claims were not presented earlier. Also Claim 18 seems (to CF) to be contradictionary to claim 1.

So I guess its back to square 1…


About Stengaard

BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years 🙂


One Response to The recent development in Triage/Trauma NGAL-patent

  1. […] I starten af August 2012 skrev  Stengaard et indlæg vedrørende traume patentet’s behandling hos de amerikanske patentmyndigheder USPTO.  The recent development in Triage/Trauma NGAL-patent. […]

Leave a Reply

Your email address will not be published. Required fields are marked *

Set your Twitter account name in your settings to use the TwitterBar Section.